The company reported disappointing clinical results.
News & Analysis: Mersana Therapeutics, Inc.
These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.
Investors are excited about the biotech's encouraging results from an early-stage clinical trial.
MRSN earnings call for the period ending March 31, 2020.
The company raised more money to keep developing potential new cancer therapies.
Clinical-trial results from the company's first proof-of-concept study were disappointing.
MRSN earnings call for the period ending March 31, 2019.
Find out what took the energy out of these stocks.
MRSN earnings call for the period ending June 30, 2018.